Cencora, Inc.'s Stock Analysis

Cencora Appoints New CFO and Reaffirms Financial Guidance

Cencora, Inc. has appointed Eva C. Boratto as the new Executive Vice President and Chief Financial Officer, effective June 29, 2026. Boratto brings extensive experience from her previous roles, including her position as CFO at Bath & Body Works and leadership roles at CVS Health Corporation and Merck & Co. She will succeed James F. Cleary, who is retiring but will assist in the transition until the end of 2026. Boratto's employment agreement includes a base salary of $1 million, an annual bonus target of 100% of her salary, and a one-time sign-on bonus of $2 million, along with a $6 million restricted stock unit award, vesting over three years.

Additionally, Cencora has reaffirmed its adjusted diluted earnings per share guidance for fiscal year 2026, maintaining a range of $17.70 to $17.90. This update follows a recent adjustment due to share repurchases. The company also confirmed its long-term growth targets, expecting adjusted operating income growth of 7% to 10% and adjusted diluted EPS growth of 10% to 14%. These announcements are significant for investors as they provide clarity on the company's financial outlook and leadership stability.

May 29, 2026 17:10:04

Cencora Reports Q2 2026 Earnings and Share Repurchase Plans

Cencora, Inc. reported a revenue of $78.4 billion for the fiscal second quarter ended March 31, 2026, marking a 3.8 percent increase year-over-year. The company achieved a GAAP diluted earnings per share (EPS) of $8.40, a significant rise from $3.68 in the same quarter the previous year. Adjusted diluted EPS also increased by 7.5 percent to $4.75. The company has raised its adjusted diluted EPS guidance for fiscal 2026 to a range of $17.65 to $17.90 and plans to repurchase $1 billion in shares by the end of the calendar year 2026.

The revenue growth was driven by a 2.9 percent increase in the U.S. Healthcare Solutions segment and a 13.0 percent increase in the International Healthcare Solutions segment. Operating income rose to $1.1 billion, reflecting a 10.3 percent increase from the prior year, despite a 20.9 percent rise in operating expenses attributed to the acquisition of OneOncology. The company also declared a quarterly cash dividend of $0.60 per common share, payable on June 1, 2026, to stockholders of record on May 15, 2026.

May 06, 2026 06:32:42

Cencora to Acquire EyeSouth Partners’ Retina Business for $1.1 Billion

Cencora, Inc. announced a definitive agreement to acquire EyeSouth Partners’ retina business for $1.1 billion, with the transaction expected to be slightly accretive to its adjusted diluted earnings per share in the first year post-closing. The acquisition will integrate EyeSouth's affiliated retina physicians into Cencora’s Retina Consultants of America, enhancing the organization's capacity to provide specialized care and innovative treatments in ophthalmology.

The transaction is contingent upon customary closing conditions, including regulatory approvals. Cencora reaffirmed its fiscal 2026 financial guidance, which does not account for the completion of this acquisition within that fiscal year. Financial advisors for the deal include BofA Securities and Citi for Cencora, while Jefferies LLC is advising EyeSouth Partners.

Mar 23, 2026 07:30:27

Cencora CFO James Cleary to Retire in June 2026

Cencora, Inc. has announced the retirement of James F. Cleary as Executive Vice President and Chief Financial Officer, effective June 30, 2026. Cleary's decision to retire is not due to any disagreements regarding the company's operations. He has served as CFO since November 2018 and will assist in the search for his successor while remaining in an advisory role through the end of 2026.

The company has reaffirmed its adjusted diluted earnings per share guidance for fiscal year 2026, maintaining a range of $17.45 to $17.75. Cencora is recognized as a leading global pharmaceutical solutions organization, ranking #10 on the Fortune 500 with over $300 billion in annual revenue. The company partners with pharmaceutical innovators to enhance market access to therapies and deliver healthcare products reliably.

Mar 17, 2026 08:45:16

Cencora Annual Meeting Results: Director Elections and Approvals

Cencora, Inc. held its 2026 Annual Meeting of Shareholders on March 5, 2026, where three significant items were voted on by shareholders. The first item involved the election of eleven directors, all of whom were successfully elected. The second item was an advisory vote on the fiscal 2025 compensation for the Company's named executive officers, which was also approved by shareholders.

The third item addressed at the meeting was the ratification of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal 2026, which received shareholder approval. No additional matters were presented for shareholder action during the Annual Meeting.

Mar 06, 2026 16:16:32

Cencora Announces $3.5 Billion Merger with Covetrus

Cencora has entered into a definitive agreement to merge its animal health business, MWI Animal Health, with Covetrus, Inc. The merger values MWI at an enterprise value of $3.5 billion, with Cencora set to receive $1.25 billion in cash, along with $800 million in preferred equity and $1.45 billion in common equity in the new combined entity. Following the merger, Cencora will hold a 34.3% ownership stake in CVET TopCo, LP, the parent company of Covetrus.

The completion of the transaction is contingent upon customary closing conditions, including necessary regulatory approvals. Cencora has indicated that its fiscal 2026 financial guidance does not currently account for the merger's completion within that fiscal year. The transaction aims to enhance service offerings and operational efficiencies within the animal health sector, benefiting stakeholders across the supply chain.

Feb 18, 2026 07:34:15

Cencora Raises $3 Billion Through Senior Notes Offering

Cencora, Inc. has successfully completed a public offering of $3.0 billion in Senior Notes, which include five tranches with varying interest rates and maturities. The notes consist of $500 million of 3.950% notes due in 2029, $500 million of 4.250% notes due in 2030, $500 million of 4.600% notes due in 2033, $1 billion of 4.900% notes due in 2036, and $500 million of 5.650% notes due in 2056. The company plans to use the net proceeds primarily to repay outstanding amounts under its 364-Day Term Credit Agreement related to its acquisition of OneOncology and for general corporate purposes.

The Senior Notes are unsecured and rank equally with Cencora’s existing and future unsecured debt. They are subject to certain covenants that limit the company’s ability to incur additional debt, create liens, or engage in significant asset transactions. Events of default include nonpayment of principal or interest and breaches of covenants. The company has filed the relevant indentures and prospectus with the SEC, and the offering was managed by Citigroup, J.P. Morgan, BofA Securities, and Wells Fargo.

Feb 13, 2026 16:36:38

Cencora Prices $3 Billion in Senior Notes Offering

Cencora, Inc. has announced the pricing of $3 billion in senior notes through a public offering. This includes five different series of notes with varying interest rates and maturities ranging from 2029 to 2056. The offering is expected to close on February 13, 2026, and is registered under an effective shelf registration statement filed with the SEC.

The company plans to use the net proceeds of approximately $2.98 billion from this offering to repay outstanding amounts under a recent credit agreement related to its acquisition of OneOncology, with any remaining funds allocated for general corporate purposes. The underwriting process involves several major financial institutions, including Citigroup, J.P. Morgan, BofA Securities, and Wells Fargo, which have previously engaged with Cencora in various capacities.

Feb 11, 2026 17:00:08

Cencora Revises Financial Reporting Structure for Investor Clarity

Cencora, Inc. has announced a revision to its financial reporting structure, effective from the first quarter of fiscal 2026. This change follows a strategic review aimed at aligning the company’s operations with its growth priorities. The new structure includes three segments: U.S. Healthcare Solutions, International Healthcare Solutions, and Other. The U.S. segment focuses on U.S. Human Health, while the International segment encompasses various global operations. The 'Other' category includes businesses currently exploring strategic alternatives.

The company filed this revision as part of its Current Report on Form 8-K to update previously reported segment results in its Annual Report for the fiscal year ending September 30, 2025. This update does not alter the company's audited consolidated financial statements but reflects the impact of the new reporting structure. Investors are encouraged to refer to the upcoming Quarterly Report for developments following the fiscal year 2025 filings.

Feb 10, 2026 08:46:43

Cencora Reports Q1 2026 Earnings and OneOncology Acquisition Details

Cencora, Inc. reported a revenue of $85.9 billion for the first quarter of fiscal 2026, marking a 5.5% increase compared to the same period last year. The company achieved a diluted earnings per share (EPS) of $2.87, up 14.8% from $2.50 in the prior year. Adjusted diluted EPS also increased by 9.4% to $4.08. The company raised its adjusted operating income guidance to a growth range of 11.5% to 13.5% following the completion of its acquisition of OneOncology, which will be consolidated within the U.S. Healthcare Solutions segment.

In addition to financial results, Cencora announced the acquisition of the majority equity interests in OneOncology for approximately $4.6 billion, financed through new debt. The U.S. Healthcare Solutions segment generated $76.2 billion in revenue, a 5.0% increase driven by market growth, while the International Healthcare Solutions segment reported $7.6 billion in revenue, a 9.6% increase. The company declared a quarterly cash dividend of $0.60 per share, payable on March 2, 2026, to shareholders of record by February 13, 2026.

Feb 04, 2026 06:31:44